Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: Cohort study

BMJ (Online)

Volumn 351, Issue , 2015, Pages

  Kesselheim, Aaron S ^a   Wang, Bo ^a   Franklin, Jessica M ^a   Darrow, Jonathan J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

ALLERGY; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONCEPTUAL FRAMEWORK; DERMATOLOGY; DOCUMENTATION; DRUG APPROVAL; DRUG DESIGN; DRUG DEVELOPMENT; DRUG PROGRAM; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; ENDOCRINOLOGY; FOOD AND DRUG ADMINISTRATION; GASTROENTEROLOGY; HEMATOLOGY; INFECTION; LOGISTIC REGRESSION ANALYSIS; MUSCULOSKELETAL DISEASE; NEUROPSYCHIATRY; ONCOLOGY; OPHTHALMOLOGY; POLICY; PRESCRIPTION; PRIORITY JOURNAL; PULMONOLOGY; REVIEW; TREND STUDY; UROGENITAL TRACT DISEASE; VALIDATION PROCESS; WORLD HEALTH ORGANIZATION; HUMAN; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TRENDS; UNITED STATES; UTILIZATION;

COHORT STUDIES; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84947259792     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h4633     Document Type: Review

References (42)

1. Food and Drug Administration. Phases of an investigation: phase 1. 21 CFR § 312.21(a). FDA, 2014.
2. Food and Drug Administration. Phases of an investigation: phase 2. 21 CFR § 312.21(b). FDA, 2014.
3. Food and Drug Administration. Phases of an investigation: phase 3. 21 CFR § 312.21(c). FDA, 2014.
4. Darrow JJ, Avorn J, Kesselheim AS. New FDA breakthrough-drug category-implications for patients. N Engl J Med 2014;370:1252-8.
5. Designation of Drugs for Rare Diseases or Conditions, 21 U.S.C. § 360bb(a)(2) (2008).
6. Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA 2011;305:2320-26.
7. Food and Drug Administration, DHHS. Investigational new drug, antibiotic, and biological drug product regulations: procedures for drugs intended to treat life-threatening and severely debilitating illnesses. Fed Regist 1988;53:41516.
8. Food and Drug Administration, DHHS. New drug, antibiotic, and biological drug product regulations; accelerated approval. Fed Regist 1992;57:58942-60.
9. Halperin JA. From investigation to marketplace: moving drugs through the system. Food Drug Cosmet Law J 1981;36:166-74.
10. Prescription Drug User Fee Act of 1992. 138 Cong Rec H9095, 1992.
11. Government Accountability Office. FDA has met most performance goals for reviewing applications. Mar 2012. www.gao.gov/assets/590/589762.pdf.
12. Kesselheim AS, Tan YT, Avorn J. The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs. Health Aff (Millwood) 2015;34:286-94.
13. Svensson S, Menkes DB, Lexchin J. Surrogate outcomes in clinical trials: a cautionary tale. JAMA Intern Med 2013;173:611-2.
14. Temple R. Mylotarg (gemtuzumab ozogamicin) approval letter (NDA 21-174). 2000. www.accessdata.fda.gov/drugsatfda-docs/appletter/2000/21174ltr.pdf.
15. Food and Drug Administration. Mylotarg (gemtuzumab ozogamicin): market withdrawal. FDA, Jun 21, 2010. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm216458.htm.
16. Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. N Engl J Med 2008;358:1354-61.
17. Lexchin J. New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? Arch Intern Med 2012;172:1680-1.
18. Olson MK. The risk we bear: the effects of review speed and industry user fees on new drug safety. J Health Econ 2008;27:175-200.
19. Nelson RJ. Regulation of investigational new drugs: "giant step for the sick and dying"? Georgetown Law J 1988;77:463-84.
20. Sanger-Katz M. Speedy drug approvals have become the rule, not the exception. NY Times 2015 May 1. www.nytimes.com/2015/05/02/upshot/speedy-drug-approvals-have-become-the-rule-not-the-exception.html?-r=0&abt=0002&abg=0.
21. Darrow JJ, Kesselheim AS. Drug development and FDA approval, 1938-2013. N Engl J Med 2014;370:e39.
22. Food and Drug Administration, DHHS. Biological products; bacterial vaccines and toxoids; implementation of efficacy review. Fed Regist 1985;240: 51002-117.
23. Lanthier M, Miller KL, Nardinelli C, et al. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011. Health Aff (Millwood) 2013;32: 1433-9.
24. World Health Organization Collaborating Center for Drug Statistics Methodology. www.whocc.no/atc-ddd-index/.2013.
25. Crawford S. Changes in FDA drugclassification and priority review policy. Am J Hosp Pharm 1992;49:2383-6.
26. Food and Drug Administration, DHHS. CDER fast track products approved since 1998 through June 1, 2010. www.fda.gov/downloads/Drugs/UCM216527.pdf.
27. Shulman SR, Brown JS. The Food and Drug Administration's early access and fast track approval initiatives: how have they worked? Food Drug Law J 1995;50:503-31.
28. Food and Drug Administration, DHHS. Accelerated and restricted approvals under Subpart H (drugs and Subpart E (biologics). 2014. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ucm121597.htm.
29. Food and Drug Administration, DHHS. CDER drug and biologic accelerated approvals as of September 30, 2011. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM278506.pdf.
30. Food and Drug Administration, DHHS. 2015. Search orphan drug designations and approvals. www.accessdata.fda.gov/scripts/opdlisting/oopd/.
31. Light DW, Lexchin J. Why do cancer drugs get such an easy ride? BMJ 2015;350:h2068.
32. Prasad V, Mailankody S. The accelerated approval of oncologic drugs: lessons from ponatinib. JAMA 2014;311:353-4.
33. Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R. Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst 2011;103:636-44.
34. Fain K, Daubresse M, Alexander GC. The Food and Drug Administration Amendments Act and postmarketing commitments. JAMA 2013;310:202-4.
35. Lexchin J. Health Canada's use of its priority review process for new drugs: a cohort study. BMJ Open 2015;5:e006816
36. Food and Drug Administration, DHHS. Drugs@FDA. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
37. Food and Drug Administration, DHHS. Expedited programs for serious conditions-drugs and biologics. May 2014. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf.
38. Food and Drug Administration Safety and Innovation Act. Pub L No 112-144. § 902, 126 Stat 993, 2012.
39. Kesselheim AS, Darrow JJ. FDA designations for therapeutics and their impact on drug development and regulatory review outcomes. Clin Pharmacol Ther 2015;97:29-36.
40. McCrimmon KK. 'Breakthrough' drugs speed paths to cures and the NBA. Health News Colorado 2013 May 15. www.healthnewscolorado.org/2013/05/15/breakthrough-drugs-speed-path-to-cures-and-the-nba/.
41. Health Policy Brief: breakthrough therapy designation. Health Aff (Millwood) May 15, 2014.
42. Avorn J, Kesselheim AS. The 21st Century Cures Act-will it take us back in time. N Engl J Med 2015;372:2473-5.